Strategic combinations: The future of oncolytic virotherapy with reovirus

Keyphrases

• Reovirus 100%
• Oncolytic Virotherapy 100%
• Oncolytic Viral Therapy 33%
• Cancer Treatment 16%
• Human Cancer 16%
• Phase II Trial 16%
• Treatment Modalities 16%
• Lysis 16%
• Chemotherapy 16%
• Tumor 16%
• Novel Therapeutics 16%
• Cancer Cells 16%
• Therapeutic Strategies 16%
• Clinical Outcomes 16%
• Activated Cells 16%
• Efficacy-toxicity 16%
• Ras Signaling 16%
• Combinational Therapy 16%
• Oncogene 16%
• Human Tumors 16%
• Radiotherapy 16%
• Multikinase Inhibitor 16%
• Immune Surveillance 16%
• Human RNA Virus 16%
• Clinical Development 16%
• Activated Ras 16%
• Anti-tumor Response 16%
• Transformed Cells 16%
• Immunosuppressive Mechanisms 16%
• Drug-resistant Tumor 16%
• RAS Pathway 16%
• Treatment Progress 16%
• Treatment-resistant 16%
• Double-stranded 16%
• Therapeutic Development 16%
• Radiotherapy Chemotherapy 16%
• Tumor Subclone 16%
• Chemotherapy Immunotherapy 16%
• RAS Genes 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Virotherapy 100%
• Reoviridae 100%
• Malignant Neoplasm 50%
• Neoplasm 33%
• Chemotherapy Regimen 33%
• Immunotherapy 16%
• Phosphotransferase Inhibitor 16%
• Immunosuppressive Agent 16%
• RNA Virus 16%
• Phase III Trials 16%

Immunology and Microbiology

• Reoviridae 100%
• Virotherapy 100%
• Signal Transduction 16%
• Cancer Cell 16%
• RNA Virus 16%
• Immunotherapy 16%
• Transformed Cell 16%
• Immunosuppressive Drug 16%
• Phosphotransferase 16%
• Kinase 16%
• Oncogene Ras 16%
• Oncogene 16%
• Immunosurveillance 16%